Penson DF, Armstrong AJ, Concepcion RS, et al. - Enzalutamide, relative to bicalutamide, is beneficial for reducing the risk of progression or death in nonmetastatic castration-resistant prostate cancer (nmCRPC), as shown in this STRIVE subgroup analysis of patients with nmCRPC.

• A total 139 patients with nmCRPC were randomized to enzalutamide 160 mg/day plus androgen deprivation therapy (ADT; n = 70) or bicalutamide 50 mg/day plus ADT (n = 69).

• Enzalutamide decreased the risk of progression or death by 76% vs bicalutamide in nmCRPC (hazard ratio [HR], 0.24), at a median of 17 months follow-up.

• Compared with bicalutamide, enzalutamide decreased risk of prostate-specific antigen progression by 82% in nmCRPC (HR, 0.18).

• Most common adverse events with enzalutamide were fatigue (36.2%), hot flush (20.3%), decreased appetite (17.4%), dizziness (17.4%), and nausea (17.4%).